Combined with a self-assembling nanoparticle vaccine and TLR7 agonist, this method elicits robust CD8+ T cell responses and synergizes with immune checkpoint inhibitors, demonstrating strong tumor suppression and extended survival in preclinical models. The gene discussed is CD8A; the disease is neoplasm.